Whole-body metabolic modelling reveals microbiome and genomic interactions on reduced urine formate levels in Alzheimer’s disease

2024 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Whole-body metabolic modelling reveals microbiome and genomic interactions on reduced urine formate levels in Alzheimer’s disease​
Martinelli, F.; Heinken, A.; Henning, A.-K.; Ulmer, M. A.; Hensen, T.; González, A. & Arnold, M. et al.​ (2024) 
Scientific Reports14(1).​ DOI: https://doi.org/10.1038/s41598-024-55960-3 

Documents & Media

License

GRO License GRO License

Details

Authors
Martinelli, Filippo; Heinken, Almut; Henning, Ann-Kristin; Ulmer, Maria A.; Hensen, Tim; González, Antonio; Arnold, Matthias; Asthana, Sanjay; Budde, Kathrin; Engelman, Corinne D.; Thiele, Ines
Abstract
Abstract In this study, we aimed to understand the potential role of the gut microbiome in the development of Alzheimer's disease (AD). We took a multi-faceted approach to investigate this relationship. Urine metabolomics were examined in individuals with AD and controls, revealing decreased formate and fumarate concentrations in AD. Additionally, we utilised whole-genome sequencing (WGS) data obtained from a separate group of individuals with AD and controls. This information allowed us to create and investigate host-microbiome personalised whole-body metabolic models. Notably, AD individuals displayed diminished formate microbial secretion in these models. Additionally, we identified specific reactions responsible for the production of formate in the host, and interestingly, these reactions were linked to genes that have correlations with AD. This study suggests formate as a possible early AD marker and highlights genetic and microbiome contributions to its production. The reduced formate secretion and its genetic associations point to a complex connection between gut microbiota and AD. This holistic understanding might pave the way for novel diagnostic and therapeutic avenues in AD management.
Issue Date
2024
Journal
Scientific Reports 
eISSN
2045-2322
Language
English
Sponsor
National Institute on Aging http://dx.doi.org/10.13039/100000049
National Institute of General Medical Sciences http://dx.doi.org/10.13039/100000057
Foundation for the National Institutes of Health http://dx.doi.org/10.13039/100000009
European Research Council http://dx.doi.org/10.13039/501100000781
Science Foundation Ireland http://dx.doi.org/10.13039/501100001602

Reference

Citations


Social Media